Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zastaprazan vs Esomeprazole in ERD with Night-time Heartburn
NCT07268820Phase 4Recruiting
- Sponsor
- Incheon St. Mary's Hospital
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of zastaprazan in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Incheon St. Mary's Hospital. Primary endpoint: Proportion of participants without sleep disturbance related to nighttime heartburn at 2 weeks. Started Jul 2025; status: recruiting.
02
Drugs
zastaprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT07268820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268820.